Debiopharm & WhiteLab Genomics Announce a Strategic Partnership to Advance Drug Target and Design in Oncology
Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the signing of a partnership with WhiteLab Genomics (WLG), a Paris and Boston-based biotech company specializing in Artificial Intelligence for Genomic Medicine R&D. This collaboration aims to achieve two key objectives. The first is to identify cancer-specific receptors that are overexpressed on the surface of cancer cells. The second is to find lead candidates capable of binding to these receptors. Once identified, these agents will be attached to the surface of lipid nanoparticles (LNPs) to enhance active tissue targeting
Lipid nanoparticles (LNPs) have emerged as a gold standard vector for drug delivery with the potential to transform the oncology landscape, particularly the genomic medicine field, through their high delivery efficacy. One of the challenges with LNPs is their tendency to accumulate in non-target organs like the liver, which limits their distribution to the desired site. To maximize LNPs potential, WLG is set to deploy its AI-powered platform to explore innovative in silico approaches for enhancing the targeted delivery capabilities of LNPs, creating new opportunities for therapeutic applications.
As a key investor in WLG, Debiopharm has consistently supported the company's innovative approaches and cutting-edge solutions through Debiopharm’s Innovation Fund. This collaboration provides a significant opportunity to validate the potential of WLG’s AI platform and strengthen their ongoing relationship.
"WhiteLab’s innovative AI platform represents a significant advancement in the field of targeted cancer therapy. By improving the specificity and delivery of lipid nanoparticles, we aim to provide more effective treatments for patients suffering from hormonal cancers," said David Del Bourgo, CEO co-founder of WLG. "Our collaboration with a leading player such as Debiopharm further demonstrates our focus on developing cutting-edge solutions that have the potential to transform cancer treatments."
“As a company specialized in drug development, we know the hardships of the field and therefore we recognize the added value of AI powered platforms like the WhiteLab Genomics’ platform applied to the early stages of drugs R&D. We look forward to fully exploiting the potential of AI based solutions to develop drugs, de-risk assets, de-risk any toxicity, and ensure that we bring the most efficacious and personalized drugs to patients.” said Betrand Ducrey, CEO of Debiopharm
About WhiteLab Genomics
Founded in 2019, backed by Y-Combinator, WhiteLab Genomics stands at the convergence of computer sciences and biology, pioneering the accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks. Based on exhaustive datasets, the platform provides in-silico simulations to discover, and design optimized payloads and vectors. WhiteLab aims to expedite the drug development process, cut costs, and accelerate the delivery of life-saving therapies to the market. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions, and innovative biotechnology companies. Recognized for their contribution to advancing the field of gene and cell therapy, WhiteLab Genomics is part of the prestigious French government supported French Tech 2030 program and recently joined the Bayer Co.Lab in Cambridge, MA, and Ginkgo Bioworks' Technology Network, marking major milestones in our international expansion.
Visit us https://whitelabgx.com/
Follow us on LinkedIn
About Debiopharm
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
Visit us www.debiopharm.com
Follow us on X @DebiopharmNews at http://twitter.com/DebiopharmNews
Follow us on LinkedIn
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017, Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds. As of September 2023, Debiopharm Innovation Fund is expanding its footprint through a new Seed financing activity.
For more information, please visit www.debiopharm.com/innovation-fund/
To learn more about investment criteria visit https://www.debiopharm.com/innovation-fund/approach/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916891953/en/
Contacts
Debiopharm
Dawn Bonine – Head of Communications
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
WhiteLab Contact
Nicolas Daniels – Ulysse communication
ndaniels@ulysse-communication.com
Tel: +33 (0)6.63.66.59.22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Electricity and Water Authority PJSC Reports a Record AED 14.6 Billion in Revenue for the First Half of 2025 and Approves Dividend Payment of AED 3.1 Billion8.8.2025 18:47:00 EEST | Press release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its first half 2025 consolidated financial results, recording first half revenue of AED 14.6 billion, EBITDA of AED 7.0 billion, operating profit of AED 3.7 billion, net profit of AED 2.9 billion and cash from operations of AED 9.2 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808832927/en/ Dubai Electricity and Water Authority PJSC reports a record AED 14.6 billion in revenue for the first half of 2025 and approves dividend payment of AED 3.1 billion (Graphic: AETOSWire) “DEWA is committed to be an innovative and sustainable corporation inspired by the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the directives of His Highn
Philippine Government and Sutherland Launch AI Academy to Equip Filipinos with Future-Ready Skills8.8.2025 16:54:00 EEST | Press release
Sutherland, a global leader in business and digital transformation, has partnered with the Philippine Government to launch a dedicated AI Academy. This strategic initiative supports the Philippine government’s broader efforts to empower the Filipino workforce for an AI-driven future. The AI Academy will offer practical, industry-aligned training designed to equip Filipino professionals with skills to integrate artificial intelligence into their work. It aims to strengthen the country’s talent pool by developing capabilities that are increasingly in demand across sectors, whether as AI specialists, prompt engineers, or cybersecurity professionals. The program will prepare participants to harness AI in driving productivity, advancing innovation, and pursuing high-value opportunities across industries. “This initiative is a vital step toward our goal of building a digitally resilient and inclusive workforce, said President Ferdinand R. Marcos Jr. “By expanding access to training in future
Baraja Appoints IP Pioneer to Lead Global Sale of Spectrum-Scan™ LiDAR IP Assets8.8.2025 16:00:00 EEST | Press release
Baraja Pty Ltd (“Baraja”), the Australian pioneer behind the revolutionary Spectrum‑Scan™ LiDAR architecture, has announced a global initiative to commercialize its full suite of patented LiDAR intellectual property and technical assets. The company has appointed IP Pioneer Group Incas the exclusive worldwide advisor to manage this competitive transaction process. Baraja redefined LiDAR performance through its Spectrum-Scan™ technology—a transformative solid-state architecture that steers the laser beam by tuning its wavelength through a dispersive prism or grating, eliminating moving parts. This breakthrough enables long-range, high-resolution 3D sensing that is inherently immune to alignment drift, sunlight, and multi-LiDAR interference. Having achieved significant technical milestones in LiDAR innovation, Baraja is now strategically evolving its business focus to pursue new frontiers in sensing and perception. This initiative will allow a new commercial partner to capitalize on the
Graanul - Expiry of Early Consent Deadline relating to the Consent Solicitation and Scheme Solicitation8.8.2025 13:54:00 EEST | Press release
Graanul: Expiry of Early Consent Deadline relating to the Consent Solicitation and Scheme Solicitation for Graanul’s: €250,000,000 Floating Rate Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354015 / Common Code 239735401 Rule 144A Notes: ISIN Number XS2397354288 / Common Code 239735428) (the “Existing Floating Rate Notes”) and €380,000,000 4.625% Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354528 / Common Code 239735452 Rule 144A Notes: ISIN Number: XS2397355095 / Common Code 239735509) (the “Existing Fixed Rate Notes” and, together with the Existing Floating Rate Notes, the “Existing Notes”) of Cullinan Holdco SCSp a special limited partnership (société en commandite spéciale) established under the laws of Luxembourg, having its registered office at 2, avenue Charles de Gaulle, L-1653, registered with the Luxembourg Register of Commerce and Companies under number B-256979 (the “Issuer” and tog
Traka Celebrates 30 Years of Innovation in Intelligent Key and Asset Management8.8.2025 12:00:00 EEST | Press release
Traka, an ASSA ABLOY company and global leader in intelligent key and equipment management solutions, is excited to announce its 30 years of innovation in intelligent key and asset management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808492250/en/ Traka is celebrating its 30th anniversary this year after its inception in 1995. What began as a custom solution for British Airways has grown into a global leader in intelligent key and asset management. Traka, now celebrating its 30th anniversary, is marking three decades of innovation, expansion, and impact across more than 30 industries worldwide. In 1995, Traka’s founder, John Kent, responded to a unique challenge: British Airways needed a secure and trackable way to manage critical keys, something the market didn’t yet offer. Kent built the first Traka key cabinet, setting the foundation for what would become a new category in access management. That first electronic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom